Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

Pfizer34 enrolled

Overview

To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved with a b-blocker, atenolol.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hypertension

Interventions

EplerenoneDRUG

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pt with essential hypertension who have never been treated or untreated within the previous 6 months Exclusion Criteria: * History of Malignant Hypertension * Sitting diastolic blood pressure \> 115mmHg or sitting Systolic blood pressure \> 200mmHg

Locations (1)

Pfizer Investigational Site

Montreal, Quebec, Canada

Outcomes

Primary Outcomes

The change from baseline to week 52 in the media/lumen ratio and the maximum % relaxation response to acetylcholine of gluteal subcutaneous resistance vessels, measured from the gluteal biopsy.

Secondary Outcomes

Will be done for both the Intent to Treat and per protocol populations, and use both the LOCF and OC methods

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.